Endocannabinoid System Modulation for Chronic Pain Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chronic pain treatments, such as NSAIDs and opioids, are inadequate in managing neuropathic pain and often interfere with the body's endogenous repair mechanisms, leading to increased inflammation and age-related discomfort due to a weakened endocannabinoid system (eCS) over the mammalian lifespan.
Innovation Solution
A composition comprising palmitoylethanolamide (PEA), docosahexaenoic acid (DHA), and beta-caryophyllene (BCP) is administered to replenish and enhance the eCS, providing anti-inflammatory and analgesic effects, thereby maintaining a robust eCS tone and reducing chronic inflammation and pain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If NSAIDs are used to treat chronic pain and inflammation, then pain relief is achieved, but the body's endogenous repair mechanisms are interfered with and inflammation resolution is impaired
Solution Approach 1:
The patent introduces endocannabinoids (anandamide, 2-AG) and other endogenous mediators as intermediary substances that naturally mediate between inflammatory signals and the body's repair mechanisms. These endogenous compounds activate CB1 and CB2 receptors to modulate inflammation resolution without blocking the body's natural repair pathways, unlike NSAIDs which directly inhibit COX enzymes.
Solution Approach 2:
The invention promotes the body's self-service capability by enhancing endogenous cannabinoid production and activity. The composition includes precursors and enzymes (FAAH, MAGL) that enable the body to produce its own pain-relieving and inflammation-resolving mediators, allowing the system to regulate itself without external interference in repair mechanisms.
2Object-affected harmful factors
If opioids are used for neuropathic pain management, then pain control is achieved, but addiction potential and serious adverse effects occur
Solution Approach 1:
The patent replaces the opioid mechanism (which acts on mu-opioid receptors in the central nervous system) with an endocannabinoid-based mechanism acting on CB1 and CB2 receptors. This substitution provides analgesic effects through a different physiological pathway that does not produce addiction or the same adverse effects, while still effectively managing neuropathic pain.
Solution Approach 2:
The invention changes the pharmacological parameters by using endogenous lipid mediators with different binding affinities and degradation rates. The endocannabinoids are rapidly synthesized and degraded locally, providing pain relief without the accumulation and tolerance development characteristic of opioids. The composition includes enzymes like FAAH and MAGL that control the temporal dynamics of pain relief.
3Object-affected harmful factors
If conventional analgesics are used for chronic pain, then some pain relief is achieved, but tolerability and effectiveness are limited over extended periods
Solution Approach 1:
The patent establishes continuous pain management through the body's ongoing production of endocannabinoids. The composition includes precursors (arachidonic acid, phospholipids) and enzymes that enable continuous synthesis of anandamide and 2-AG, providing sustained pain relief without the dosing intervals and tolerance issues of conventional analgesics. The system operates continuously as long as the precursors are available.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination effectively mitigates age-related discomfort by enhancing the endocannabinoid system's ability to regulate homeostasis, reducing chronic inflammation, and providing significant pain relief without the side effects associated with traditional analgesics.
Implementation Method 1
A composition comprising palmitoylethanolamide (PEA), docosahexaenoic acid (DHA), and beta-caryophyllene (BCP) is administered to replenish and enhance the eCS, providing anti-inflammatory and analgesic effects
Implementation Method 2
The combination effectively mitigates age-related discomfort by enhancing the endocannabinoid system's ability to regulate homeostasis, reducing chronic inflammation
Implementation Method 3
providing significant pain relief without the side effects associated with traditional analgesics
Data Source
AI summary
Compositions and methods for prophylactically sustaining and/or maintaining a robust endocannabinoid system in patients for modulating excess inflammatory response and inflammatory diseases over the mammalian lifespan to mitigate age-related discomfort. Specifically, a method of uniquely treating inflammatory and neuropathic pain in a mammal by administering a synergistic pharmaceutical daily dosage form comprising: palmitoylethanolamide (PEA), beta-caryophyllene (BCP) and docosahexaenoic acid (DHA).